SIRT2 and breast cancer: The authors previously established a fluorescence-based method for SIRT2 inhibition tests [38,39,40], and identified a series of N-(3-(phenoxymethyl)phenyl)acetamide derivatives as highly selective SIRT2 inhibitors [38,41], some of which showed inhibitory activities against SIRT2 highly-expressed human breast cancer cells and non-small cell lung cancer cells.